Date:	2022-	03-07
Date.	~~~	03-07

Your Name: Simeng Zhang

Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large

Chinese hypertensive population: A cross-sectional study

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), the National Natural Science Foundation of China (No. 81800403 to Simeng Zhang), and the Ausa pharmaceutical company, Shenzhen, China.	
2		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	None	
ь	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Name	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the National Natural Science Foundation of China (No. 81800403 to Simeng Zhang). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
Your Name:Jie Liu
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	_	Decimand and have a series for	No	
speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None	5		None None	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Mone None				
educational events Payment for expert testimony None Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None				
6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None			No	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	6		None None	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None		testimony		
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
8 Patents planned, issued or pendingNone	7		None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None		meetings and/or travel		
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	-	None None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	9		None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
committee or advocacy group, paid or unpaid 11 Stock or stock optionsNone	10		None	
group, paid or unpaid 11 Stock or stock options None		I		
11 Stock or stock options None		- · · · · · · · · · · · · · · · · · · ·		
	11	Stock or stock options	None	
	12	Receipt of equipment, materials, drugs, medical	None	
writing, gifts or other				
services				
13 Other financial or non- None	13		None	
financial interests		financial interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
Your Name:Xin Jia
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frames Since the initial planning of the work	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	_	Decimand and have a series for	No	
speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None	5		None None	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Mone None				
educational events Payment for expert testimony None Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None				
6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None			No	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	6		None None	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None		testimony		
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
8 Patents planned, issued or pendingNone	7		None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None		meetings and/or travel		
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	-	None None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	9		None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
committee or advocacy group, paid or unpaid 11 Stock or stock optionsNone	10		None	
group, paid or unpaid 11 Stock or stock options None		I		
11 Stock or stock options None		- · · · · · · · · · · · · · · · · · · ·		
	11	Stock or stock options	None	
	12	Receipt of equipment, materials, drugs, medical	None	
writing, gifts or other				
services				
13 Other financial or non- None	13		None	
financial interests		financial interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-0	7
Your Name:	Tao Zhang
Manuscript Title:	Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hyperter	nsive population: A cross-sectional study
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	None	
	imanciai interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07	
Your Name:	Xianhui Qin
Manuscript Title: I	nvestigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertens	ive population: A cross-sectional study
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	_	Decimand and have a series for	No	
speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None	5		None None	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Mone None				
educational events Payment for expert testimony None Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None				
6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None			No	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	6		None None	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None		testimony		
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
8 Patents planned, issued or pendingNone	7		None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None		meetings and/or travel		
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None Stock or stock options None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	8	-	None None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None	9		None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None				
committee or advocacy group, paid or unpaid 11 Stock or stock optionsNone	10		None	
group, paid or unpaid 11 Stock or stock options None		I		
11 Stock or stock options None		- · · · · · · · · · · · · · · · · · · ·		
	11	Stock or stock options	None	
	12	Receipt of equipment,	None	
materials, drugs, medical		_		
writing, gifts or other				
services				
13 Other financial or non- None	13		None	
financial interests		financial interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-0	7
Your Name:	_Senhao Jia
Manuscript Title:	Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hyperter	sive population: A cross-sectional study
Manuscript numl	per (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comm ents (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None
	manuscript writing or educational events	
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or	None
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	None
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other services	
13	Other financial or non-	None
	financial interests	

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
our Name:Yue Li
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	None	
	imanciai interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-0	7
Your Name:	Lishun Liu
Manuscript Title:	Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hyperter	sive population: A cross-sectional study
Manuscript numl	per (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-0	7
Your Name:	Yuxiang Song
Manuscript Title:	Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hyperten	sive population: A cross-sectional study
Manuscript numb	per (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comm ents (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None
	manuscript writing or educational events	
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
	meetings and, or travel	
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or	None
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	None
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other services	
13	Other financial or non-	None
	financial interests	

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-0	07
Your Name:	Shangwei Zuo
Manuscript Title	Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hyperte	nsive population: A cross-sectional study
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	None	
	imanciai interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
Your Name:_ Ren Wei
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a larg
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	None	
	imanciai interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07_	
Your Name:	_ Chen Duan
Manuscript Title: In	vestigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensiv	re population: A cross-sectional study
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	specifications/Commen ts (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	None	
	imanciai interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
Your Name: Zhongyin Wu
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	None	
	imanciai interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07		
Your Name:	Yangyang Ge	
Manuscript Title: I	estigating the inverse association between glycaemia and abdominal aortic dilatation in a lar	ge
Chinese hypertens	population: A cross-sectional study	
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comm ents (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None
	manuscript writing or educational events	
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or	None
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	None
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other services	
13	Other financial or non-	None
	financial interests	

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-0	7
Your Name:	Xian Wang
Manuscript Title	Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hyperter	nsive population: A cross-sectional study
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	NoneNone	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
Your Name: Wei Kong
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Commen ts (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Descipt of anytings and	Nege	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022-03-07_	
Your Name:	_Xiping Xu
Manuscript Title: In	stigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chinese hypertensiv	population: A cross-sectional study
Manuscript number	f known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Com ments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	•		
7	Support for attending meetings and/or travel	None	
	G ,		
8	Patents planned, issued or	None	
	pending		
	5		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	NOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07	
Your Name: Qiang Wang	
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a la	arge
Chinese hypertensive population: A cross-sectional study	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Com ments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel		
	and an an an an an an		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	Name	
13	Other financial or non- financial interests	None	
	illiancidi lillerests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_ 2022-03-07
Your Name: Yong Huo
Manuscript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a larg
Chinese hypertensive population: A cross-sectional study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Com ments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
	and an an an an an an		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	Name	
13	Other financial or non- financial interests	None	
	illiancidi lillerests		

The author report that the study was supported by the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703). The study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement:

Date:_	2022-03-07
Your N	ame: Wei Guo
Manus	cript Title: Investigating the inverse association between glycaemia and abdominal aortic dilatation in a large
Chines	e hypertensive population: A cross-sectional study
Manus	cript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Com ments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding support from the National Key Research and Development Project (No. 2020YFC1107700 to Wei Guo), the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the Ausa pharmaceutical company, Shenzhen, China.	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	INUITE	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author report that the study was supported by the National Key Research and Development Project (No. 2020YFC1107700 to Wei Guo), the Eleventh Five-year Plan in Health Care Foundation of PLA (No. 09BJZ04), the Ministry of Science and Technology of the People's Republic of China (No. 2012zx09101105), the Major State Basic Research Development Program of China (973 program, No. 2012CB517703), and the study was also sponsored by the Ausa pharmaceutical company, Shenzhen, China.

Please place an "X" next to the following statement to indicate your agreement: